Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study
Karin G. F. Gerritsen, Roel Broekhuizen(Utrecht University), Jan Willem Leeuwis(University Medical Center Utrecht), Hendrik M. Nathoe, Roel Goldschmeding(University Medical Center Utrecht), Stefan H. van Vuuren(University Medical Center Utrecht), Marianne C. Verhaar(Utrecht University), Lucas L. Falke(University Medical Center Utrecht), Tri Q. Nguyen(Utrecht University), Frank L.J. Visseren(University Medical Center Utrecht), Robbert J. Kok(Utrecht University), Gert Jan de Borst
Cited by 23
Related Papers
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
|European Heart Journal|2021|6.1k
Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
|New England Journal of Medicine|2008|1.2k
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305